

21 Jul 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J's Spravato on track for blockbuster status; US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and Legend buyout rumors validate China biotech.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 19 July 2024, including: [Johnson & Johnson's Spravato on track for blockbuster status](#); US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and [Legend Biotech Corp. buyout rumors validate China biotech](#).

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J&J's Spravato On Track To Be A Blockbuster, Five Years In](#)" - Scrip, 17 Jul, 2024.)

(Also see "[Rezdiffra Uptake Held Up By Payers, But Not Biopsy Requirements](#)" - Scrip, 15 Jul, 2024.)

(Also see "[CNS Drugs Are Surprisingly Valuable](#)" - Scrip, 15 Jul, 2024.)

(Also see "[Obesity Rules Large-Cap Stocks In First Half Of 2024](#)" - Scrip, 16 Jul, 2024.)

(Also see "[Legend Buyout Report Boosts, Validates China Biotech](#)" - Scrip, 16 Jul, 2024.)

[Click here to explore this interactive content online](#) 